A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive
Junichi Uchino, MD, PhD
Advertisement
Articles by Junichi Uchino, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
2
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
3
Radiation Oncology Trials You May Have Missed at ASCO 2026
4
Camizestrant Extends PFS and PFS2 in ESR1-Mutated Advanced Breast Cancer
5